VIRGINIA RETIREMENT SYSTEMS ET Al Acquires Shares of 25,440 Thermo Fisher Scientific Inc. $TMO

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,440 shares of the medical research company’s stock, valued at approximately $14,741,000.

A number of other large investors have also recently bought and sold shares of the stock. Boyd Watterson Asset Management LLC OH grew its holdings in Thermo Fisher Scientific by 0.7% during the 4th quarter. Boyd Watterson Asset Management LLC OH now owns 3,771 shares of the medical research company’s stock valued at $2,185,000 after buying an additional 28 shares during the last quarter. Seelaus Asset Management LLC grew its holdings in Thermo Fisher Scientific by 3.0% during the 4th quarter. Seelaus Asset Management LLC now owns 1,717 shares of the medical research company’s stock valued at $995,000 after buying an additional 50 shares during the last quarter. ESG Planning DBA Harper Investing grew its holdings in Thermo Fisher Scientific by 10.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 2,522 shares of the medical research company’s stock valued at $1,462,000 after buying an additional 236 shares during the last quarter. Meridian Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 3.3% during the 4th quarter. Meridian Wealth Management LLC now owns 1,250 shares of the medical research company’s stock valued at $724,000 after buying an additional 40 shares during the last quarter. Finally, Win Advisors Inc. grew its holdings in Thermo Fisher Scientific by 61.1% during the 4th quarter. Win Advisors Inc. now owns 1,521 shares of the medical research company’s stock valued at $881,000 after buying an additional 577 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $446.50 on Thursday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The stock’s fifty day simple moving average is $488.70 and its 200-day simple moving average is $543.73. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $165.93 billion, a price-to-earnings ratio of 24.55, a price-to-earnings-growth ratio of 2.03 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the firm earned $5.15 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a $0.47 dividend. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on TMO. Barclays lowered their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Morgan Stanley reiterated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. TD Cowen lowered their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Finally, UBS Group restated a “neutral” rating and set a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $619.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.